Table of Contents Author Guidelines Submit a Manuscript
Dermatology Research and Practice
Volume 2018 (2018), Article ID 5801280, 4 pages
https://doi.org/10.1155/2018/5801280
Review Article

Impetigo Herpetiformis: Review of Pathogenesis, Complication, and Treatment

Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence should be addressed to Sahar Dadkhahfar; moc.liamg@rafhahkdad.rahas

Received 20 January 2018; Accepted 5 March 2018; Published 4 April 2018

Academic Editor: E. Helen Kemp

Copyright © 2018 Nastaran Namazi and Sahar Dadkhahfar. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. E. Chang, H. H. Kim, J. H. Choi, and etal., “Impetigo herpetiformis followed by generalized pustular psoriasis: more evidence of same disease entity,” International Journal of Dermatology, vol. 42, no. 9, pp. 754-755, 2003. View at Google Scholar
  2. K. Sugiura, A. Takemoto, M. Yamaguchi, and H. Takahashi, “The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist,” Journal of Investigative Dermatology, vol. 133, no. 11, pp. 2514–2521, 2013. View at Google Scholar
  3. T. H. Henson, “Recurrent pustular rash in a pregnant woman,” JAMA Dermatology, vol. 136, no. 8, pp. 1055–1060, 2000. View at Publisher · View at Google Scholar
  4. Z. Erbagci and S. Erkilic, “A case of recurrent impetigo herpetiformis with a positive family history,” International Journal of Clinical Practice, vol. 54, no. 9, pp. 619-620, 2000. View at Google Scholar
  5. N. Setta-Kaffetzi, A. A. Navarini, V. M. Patel et al., “Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes,” Journal of Investigative Dermatology, vol. 133, no. 5, pp. 1366–1369, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Sugiura, N. Oiso, S. Iinuma et al., “IL36RN mutations underlie impetigo herpetiformis,” Journal of Investigative Dermatology, vol. 134, no. 9, pp. 2472–2474, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Sugiura, A. Nakasuka, H. Kono, M. Kono, and M. Akiyama, “Impetigo herpetiformis with IL36RN mutations in a Chinese patient: A founder haplotype of c.115+6T>C in East Asia,” Journal of Dermatological Science, vol. 79, no. 3, pp. 319-320, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. U. M. Fouda, R. M. Fouda, H. M. Ammar, M. Salem, and M. El Darouti, “Impetigo herpetiformis during the puerperium triggered by secondary hypoparathyroidism: A case report,” Cases Journal, vol. 2, no. 12, article no. 9338, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Lakshmi, C. R. Srinivas, S. Paul, T. V. Chitra, K. Kanchanamalai, and L. S. Somasundaram, “Recurrent impetigo herpetiformis with diabetes and hypoalbuminemia successfully treated with cyclosporine, albumin, insulin and metformin,” Indian Journal of Dermatology, vol. 55, no. 2, pp. 181–184, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Guerriero, S. Lanza Silveri, T. Sisto, D. Rosati, and etal., “Impetigo herpetiformis occurring during N-butyl-scopolammonium bromide therapy in pregnancy: case report,” Journal of Biological regulators & Homeostatic Agents, vol. 22, no. 2, pp. 141–144, 2008. View at Google Scholar
  11. Y. Kuwabara, A. Sato, H. Abe, S. Abe, N. Kawai, and T. Takeshita, “Ritodrine-induced pustular eruptions distinctly resembling impetigo herpetiformis,” Journal of Nippon Medical School, vol. 78, no. 5, pp. 329–333, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Sardy, K. Preisz, M. Berecz, C. Horvath, S. Karpati, and A. Horvath, “Methotrexate treatment of recurrent impetigo herpetiformis with hypoparathyroidism,” Journal of the European Academy of Dermatology and Venereology, vol. 20, no. 6, pp. 742-743, 2006. View at Publisher · View at Google Scholar
  13. R. Wolf, U. Tartler, H. Stege, M. Megahed, and T. Ruzicka, “Impetigo herpetiformis with hyperparathyroidism,” Journal of the European Academy of Dermatology and Venereology, vol. 19, no. 6, pp. 743–746, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Breier-Maly, B. Ortel, F. Breier, J. B. Schmidt, and H. Hönigsmann, “Generalized pustular psoriasis of pregnancy (impetigo herpetiformis),” Dermatology, vol. 198, no. 1, pp. 61–64, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. H. Huang, Y. P. Chen, C. C. Liang, Y. L. Chang, and C. C. Hsieh, “Impetigo herpetiformis with gestational hypertension: A case report and literature review,” Dermatology, vol. 222, no. 3, pp. 221–224, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. K. S. Lim, M. B. Tang, and P. P. Ng, “Impetigo herpetiformis—A rare dermatosis of pregnancy associated with prenatal complications,” ANNALS Academy of Medicine Singapore, vol. 34, no. 9, pp. 565–568, 2005. View at Google Scholar
  17. B. Doebelin, J. L. Estival, A. Nau, and etal., “Impetigo herpetiformis and Ondine curse,” Annales De Dermatologie Et De Venereologie, vol. 132, pp. 559–561, 2005. View at Google Scholar
  18. O. Y. Oumeish, S. E. Farraj, and A. S. Bataineh, “Some Aspects of Impetigo Herpetiformis,” JAMA Dermatology, vol. 118, no. 2, pp. 103–105, 1982. View at Publisher · View at Google Scholar · View at Scopus
  19. Q.-Q. Gao, M.-R. Xi, and Q. Yao, “Impetigo herpetiformis during pregnancy: A case report and literature review,” Dermatology, vol. 226, no. 1, pp. 35–40, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. S. L. Carmichael, G. M. Shaw, C. Ma, M. M. Werler, S. A. Rasmussen, and E. J. Lammer, “Maternal corticosteroid use and orofacial clefts,” American Journal of Obstetrics & Gynecology, vol. 197, no. 6, pp. 585–683, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. C.-C. Chi, R. T. Mayon-White, and F. T. Wojnarowska, “Safety of topical corticosteroids in pregnancy: A population-based cohort study,” Journal of Investigative Dermatology, vol. 131, no. 4, pp. 884–891, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Chi, G. Kirtschig, W. Aberer et al., “Evidence-based (S3) guideline on topical corticosteroids in pregnancy,” British Journal of Dermatology, vol. 165, no. 5, pp. 943–952, 2011. View at Publisher · View at Google Scholar
  23. S. Lehrhoff and M. K. Pomeranz, “Specific dermatoses of pregnancy and their treatment,” Dermatologic Therapy, vol. 26, no. 4, pp. 274–284, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Patsatsi, T. D. Theodoridis, D. Vavilis et al., “Cyclosporine in the management of impetigo herpetiformis: A case report and review of the literature,” Case Reports in Dermatology, vol. 5, no. 1, pp. 99–104, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Kapoor and J. R. Kapoor, “Cyclosporine resolves generalized pustular psoriasis of pregnancy,” JAMA Dermatology, vol. 142, no. 10, pp. 1373–1375, 2006. View at Google Scholar · View at Scopus
  26. B. B. Oz, R. Hackman, T. Einarson, and G. Koren, “Pregnancy outcome after cyclosporine therapy during pregnancy: A meta-analysis,” Transplantation, vol. 71, no. 8, pp. 1051–1055, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. J. E. Murase, M. M. Heller, and D. C. Butler, “Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy,” Journal of the American Academy of Dermatology, vol. 70, no. 3, pp. 401–415, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. G. R. Tintinger, R. Anderson, and C. Feldman, “Pharmacological approaches to regulate neutrophil activity,” Seminars in Immunopathology, vol. 35, no. 4, pp. 395–409, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Luan, S. Han, Z. Zhang, and X. Liu, “Personal treatment experience for severe generalized pustular psoriasis of pregnancy: Two case reports,” Dermatologic Therapy, vol. 27, no. 3, pp. 174–177, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Puig, D. Barco, and A. Alomar, “Treatment of psoriasis with anti-TNF drugs during pregnancy: Case report and review of the literature,” Dermatology, vol. 220, no. 1, pp. 71–76, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. C. D. Chambers and D. L. Johnson, “Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy,” Birth Defects Research Part A - Clinical and Molecular Teratology, vol. 94, no. 8, pp. 607–611, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Andrulonis and L. K. Ferris, “Treatment of severe psoriasis with ustekinumab during pregnancy,” Journal of Drugs in Dermatology (JDD), vol. 11, no. 10, pp. 1240-1241, 2012. View at Google Scholar · View at Scopus
  33. K. Bozdag, S. Ozturk, and M. Ermete, “A case of recurrent impetigo herpetiformis treated with systemic corticosteroids and narrowband UVB,” Cutaneous and Ocular Toxicology, vol. 31, no. 1, pp. 67–69, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. R. S. Stern and R. Lange, “Outcomes of pregnancies among women and partners of men with a history of exposure to methoxsalen photochemotherapy (PUVA) for the treatment of psoriasis,” JAMA Dermatology, vol. 127, no. 3, pp. 347–350, 1991. View at Publisher · View at Google Scholar · View at Scopus
  35. I. A. Bukhari, “Impetigo herpetiformis in a primigravida: successful treatment with etretinate,” Journal of drugs in dermatology : JDD, vol. 3, no. 4, pp. 449–451, 2004. View at Google Scholar · View at Scopus